Two Things Changed for Oregon Psilocybin Facilitators in January. Most of You Don't Know About Both of Them.

For renewal applications received on or after January 1, 2026, all licensed facilitators must complete at least four hours of continuing facilitator education during their annual license period to be eligible for renewal. The clock starts from the date your license was first issued, not from January 1.

This is where most facilitators I've spoken with are confused. The rule says valid CE can be offered by:

1. A training program with curricula approved by OPS, or
2. An organization or conference that has been approved to offer continuing education for other types of professional licenses or certifications

That second category is significant. It means NBCC-approved CE providers — the same approval that governs continuing education for licensed counselors, social workers, and therapists — can count toward your OPS facilitator renewal. You don't have to go back to your original $9,000+ training program.

There's a constraint that doesn't get mentioned enough: the content has to matter. Per OAR 333-333-3300, continuing facilitator education must consist of skills and knowledge that are relevant to the core curriculum described in OAR 333-333-3050 and OAR 333-333-3060.

Those two rules cover the original OPS training curriculum categories: psilocybin pharmacology, preparation and integration practice, client safety and screening, scope of practice, facilitation ethics, and group facilitation skills, among others.

A generic ethics course on insurance billing or documentation doesn't qualify. A course on medication interactions in psilocybin contexts does. A course on clinical assessment of psychedelic candidates does. The provider approval and the subject matter relevance are both required — either alone isn't sufficient.

You'll need to be able to provide documentation that describes the education received, who provided the training, and the number of hours. OPS developed an updated Continuing Facilitator Education Hours Log for this purpose; use the version dated January 1, 2026, not the prior version.

The second change has been in the works since HB 2387 passed in the 2025 legislative session and was signed by Governor Kotek in May 2025. It took effect January 1, 2026.

Here's what it does: if you hold a facilitator license and a license from one of seven named healthcare boards, you can now legally conduct preparation and integration sessions under both licenses simultaneously. The bill specifically names the Oregon Board of Licensed Professional Counselors and Therapists among those seven boards.

Prior to this, dual-licensed clinicians were operating in genuine legal ambiguity. Could a licensed therapist who was also a facilitator draw on their clinical training in a prep session? Could they use clinical assessment tools? The scope of practice boundaries were unclear, and the professional liability exposure was real. That ambiguity is now resolved.

Dual-licensed facilitators can now bring their full clinical skill set to preparation and integration work within the OPS framework. A licensed therapist working as a facilitator can integrate their therapeutic training in ways that weren't clearly permitted before. This is a meaningful expansion of what dual-licensed clinicians can offer their clients.

One important limit: the law specifies that psilocybin administration itself cannot be mixed with concurrent health care services. The clinical license applies to prep and integration, not to the administration session.

If you're dual-licensed and haven't acted on this yet, two things:

1. Notify OHA: dual-licensed facilitators are required to notify the Oregon Health Authority in a form and manner prescribed by the Authority.
2. Update your forms: OPS updated three required operational forms that must be in use as of January 1, 2026:

• Client Information Form
• 303 Client Data Form
• Psilocybin Product and End of Session form

All three are available on the OPS website. If you're still using the prior versions, you're out of compliance.

Mandatory CE creates a market. It's worth being direct about what kind of market.

A 2025 peer-reviewed study of Oregon's early facilitator workforce found that across 16 active training programs, the mean tuition was $9,359 — and the majority of the 106 facilitators surveyed reported those training expenses as a moderate-to-severe financial strain. Half of programs offered diversity scholarships. Half.

The same programs that collected that tuition are now positioned to sell ongoing education to the same facilitators. That's not an accusation — it's a structural observation. The question is whether the field builds a CE ecosystem that compounds those costs, or one that doesn't.

The rule creates room for the latter. NBCC-approved providers offering topically relevant CE at accessible price points are a legitimate pathway. Whether facilitators know that is a different problem — one I'm trying to contribute to solving, which is part of why I wrote this post.

For dual-licensed clinicians, HB 2387 doesn't just resolve a legal ambiguity — it opens up clinical questions that the field hasn't fully grappled with. One of the most pressing is medication interactions, particularly SSRIs.

Estimates suggest that a significant proportion of OPS clients may be using SSRIs. The clinical picture here is genuinely complicated, and not in the direction most facilitators assume.

The interaction is far from straightforward. A 2024 content analysis of Reddit posts found that about half of people who reported combining SSRIs with psilocybin described reduced intensity of the acute experience, while a smaller portion reported potential adverse effects.

The intuitive clinical response — taper the SSRI before the session — is actually not well supported by the data. A 2024 exploratory analysis from Imperial College London found that patients who had discontinued SSRIs prior to psilocybin treatment had worse outcomes than unmedicated patients at trial entry, suggesting that discontinuation itself may diminish response. A 2021 RCT found that escitalopram pretreatment reduced adverse effects of psilocybin without affecting positive mood outcomes.

The picture that emerges is one of genuine clinical complexity — not a clean contraindication, not a simple taper-and-proceed protocol. This is exactly the kind of nuance that dual-licensed clinicians are now better positioned to address, and that continuing education should cover.

If you're an Oregon facilitator, here's what to do with this:

• Find your renewal date. Your license anniversary is the date it was first issued. Count back one year — your CE must be completed within that window.
• Log your hours. Use the updated Continuing Facilitator Education Hours Log.
• Check subject matter, not just provider. Any CE you're counting needs to cover OPS core curriculum topics, not just come from an approved provider.
• If you're dual-licensed: Notify OHA, and verify you're using the updated 2026 versions of all three required forms.

If you have questions about whether specific CE content qualifies, email the OPS licensing team.